The signing of a rebate agreement with pharmacy benefit managers is a positive development for Better Therapeutics, as it represents a significant step towards securing broad coverage for its AspyreRx diabetes treatment. Although the financial terms were not disclosed, the agreement is likely to enhance the company's revenue prospects and market penetration for AspyreRx. The positive impact on BTTX's stock price in the short term is anticipated due to the potential for increased sales and market share.